Fig. 7: Biomarkers of immunoediting (2). | Nature Communications

Fig. 7: Biomarkers of immunoediting (2).

From: Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

Fig. 7

Microphotographs of HLA class I and CD8 immunohistochemistry for representative patients in each ICR/GIE class (left). The plots represent the ICR and GIE sample scores, percentages of HLA-positive cells, and density of CD8 T cells. The presented data was derived from one experimental run independently reviewed by three different trained scientists. Source data are provided as a Source Data file.

Back to article page